Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant

Leukemia and Lymphoma

Volumn 55, Issue 5, 2014, Pages 1053-1060

  Harrison, Simon J ^a   Hsu, Andy K ^a   Neeson, Paul ^a   Younes, Anas ^b   Sureda, Anna ^c,d   Engert, Andreas ^e   Prince, H Miles ^a   Li, Martha ^f   Savage, Paula ^f   Bugarini, Roberto ^g   Williams, Denise ^f   Squier, Margaret ^f   Ritchie, David S ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^f NOVARTIS PHARMA AG   (Switzerland)

^g NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Chemokines; Cytokines; Hodgkin lymphoma; Panobinostat; TARC; Transforming growth factor

Indexed keywords

EOTAXIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MACROPHAGE DERIVED CHEMOKINE; PANOBINOSTAT; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; HYDROXAMIC ACID; INDOLE DERIVATIVE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; ADOLESCENT; AUTOTRANSPLANTATION; BLOOD; CANCER STAGING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR VOLUME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CHEMOKINE CCL17; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; HYDROXAMIC ACIDS; INDOLES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; TUMOR BURDEN; YOUNG ADULT;

EID: 84899743371     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.820287     Document Type: Article

References (28)

1. Kuppers R, Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol 1998; 16: 471-493.
2. Maggio E, van den Berg A, Diepstra A, et al. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 2002; 13(Suppl. 1): 52-56.
3. Teruya-Feldstein J, Tosato G, Jaff e E S. The role of chemokines in Hodgkin's disease. Leuk Lymphoma 2000; 38: 363-371.
4. van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol 1999; 154: 1685-1691.
5. Buglio D, Georgakis GV, Hanabuchi S, et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008; 112: 1424-1433.
6. Kapp U, Yeh WC, Patterson B, et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 1999; 189: 1939-1946.
7. Herbst H, Foss H D, Samol J, et al. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood 1996; 87: 2918-2929.
8. Hsu SM, Lin J, Xie SS, et al. Abundant expression of transforming growth factor-beta 1 and-beta 2 by Hodgkin's Reed-Sternberg cells and by reactive T lymphocytes in Hodgkin's disease. Hum Pathol 1993; 24: 249-255.
9. Wolf J, Kapp U, Bohlen H, et al. Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood 1996; 87: 3418-3428.
10. Newcom S R, G u L. T ransforming growth factor beta 1 messenger RNA in Reed-Sternberg cells in nodular sclerosing Hodgkin's disease. J Clin Pathol 1995; 48: 160-163.
11. Plattel W, Van Den Berg A, Van der Graaf A M, et al. Mid-Treatment plasma levels of thymus activated and regulated chemokine (TARC) predict treatment outcome in classical Hodgkin lymphoma patients. Blood 2010; 116(Suppl. 1): Abstract 748.
12. Younes A, Bartlett N L, Leonard J P, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812-1821.
13. Fehniger T A, Larson S, Trinkaus K, et a l. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical hodgkin lymphoma. Blood 2011; 118: 5119-5125.
14. Buglio D, Mamidipudi V, Khaskhely N M, et a l. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism. Br J Haematol 2010; 151: 387-396.
15. Younes A, Oki Y, Bociek RG, et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: An open-label, single-Arm, phase 2 trial. Lancet Oncol 2011; 12: 1222-1228.
16. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges. Cancer Lett 2009; 280: 233-241.
17. Prince HM, Bishton MJ, Johnstone RW. Panobinostat (LBH589): A potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 2009; 5: 601-612.
18. Joos S, Granzow M, Holtgreve-Grez H, et al. Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int J Cancer 2003; 103: 489-495.
19. Kube D, Holtick U, Vockerodt M, et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood 2001; 98: 762-770.
20. Wang Y, Fiskus W, Chong DG, et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 2009; 114: 5024-5033.
21. Shao W, Growney JD, Feng Y, et al. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance. Int J Cancer 2010; 127: 2199-2208.
22. Baus D, Nonnenmacher F, Jankowski S, et al. STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical hodgkin lymphoma cell line. Leukemia 2009; 23: 1885-1893.
23. Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: Results of a phase II study. J Clin Oncol 2012; 30: 2197-2203.
24. Cheson BD, Pfi stner B, Juweid ME, et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
25. Flavell J R, Baumforth K R, Wood V H, et al. Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. Blood 2008; 111: 292-301.
26. Niens M, Visser L, Nolte I M, et al. Serum chemokine levels in Hodgkin lymphoma patients: Highly increased levels of CCL17 and CCL22. Br J Haematol 2008; 140: 527-536.
27. Younes A, Hagenbeek A, Coiffier B. Optimising the lymphoma response criteria in the era of targeted therapy. Lancet Oncol 2011; 12: 616-617.
28. Hoos A, Britten CM, Huber C, et al. A methodological framework to enhance the clinical success of cancer immunotherapy. Nat Biotechnol 2011; 29: 867-870.